Human embryonic stem cell research represents a new era in the field of spinal cord injuries

companiesandmarkets.com

2010-03-15 17:01:02 - Stakeholder Opinions: Spinal Cord Injury - Attractive niche market with multi-billion dollar potential - a new market research report on companiesandmarkets.com

www.companiesandmarkets.com/Summary-Market-Report/stakeholder-op ..

Advances in understanding the pathophysiology of spinal cord injury (SCI) over the past 2 decades have given rise to several therapeutic strategies that are presently being examined in Phase II/I clinical trials. Furthermore, President Obama´s March 2009 decision to overturn restrictions on human embryonic stem cell research represents a new era in the field of spinal cord injuries.

Scope

*Analysis of the

 

 

patient potential of spinal cord injury across the seven major markets and rest of world.

*Review of key unmet clinical needs in the treatment of spinal cord injury and current pipeline treatments.

*Identification of key opportunities and threats facing developers of treatments for spinal cord injury.

*Insight from four internationally recognized key opinion leaders in the field of spinal cord injuries.

Highlights

Therapeutic interventions for SCI need not necessarily provide a complete restoration of anatomic connections in order to lead to functional improvements and enhance patients´ quality of life. Controversy continues to surround the use of methylprednisolone as an acute treatment for SCI, indicating a need for approved neuroprotective treatments.

Alseres Pharmaceuticals´s Cethrin (a recombinant fusion protein) has demonstrated a measurable effect on neurological recovery after SCI in a Phase I/IIa clinical trial. However, with its Phase II clinical program currently on hold, future development of Cethrin is uncertain.

President Obama´s March 2009 decision to lift restrictions on US federal funding for research involving human embryonic stem cells has provided developers with a greater deal of freedom with regards to research into SCI.

Reasons to Purchase

*Quantify the incidence of spinal cord injury and identify key clinical unmet needs.

*Assess the opportunities and threats facing developers in the spinal cord injury market.

*Utilize pipeline product profiles to identify potential in-licensing opportunities.